BEDFORD, Mass.--(BUSINESS WIRE)--Jul. 30, 2014--
Ocular Therapeutix (Nasdaq: OCUL), a biopharmaceutical company focused
on the development and commercialization of innovative therapies for
diseases and conditions of the eye, announced today the closing of its
initial public offering of 5,000,000 shares of its common stock at a
public offering price of $13.00 per share, resulting in net proceeds of
approximately $60.5 million after deducting underwriting discounts and
commissions, and estimated offering expenses. All of the shares of
common stock in the offering were sold by Ocular Therapeutix.
Morgan Stanley, Cowen and Company and RBC Capital Markets acted as joint
book-running managers for the offering. Oppenheimer & Co. acted as a
A copy of the final prospectus relating to the offering may be obtained
from Morgan Stanley & Co. LLC, attention: Prospectus Department, 180
Varick Street, 2nd Floor, New York, New York 10014; Cowen and Company,
LLC, c/o Broadridge Financial Services, attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY, 11717; or RBC Capital
Markets, LLC, attention: Equity Syndicate, Three World Financial Center,
200 Vesey Street, 8th Floor, New York, NY 10281-8098.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on July 24, 2014.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities, in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix’s lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain and
Phase 2 clinical development for glaucoma, ocular hypertension and
allergic conjunctivitis. The Company is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix’s first product, ReSure®
Sealant, was approved by the U.S. Food and Drug Administration in
January 2014 to seal corneal incisions following cataract surgery.
Source: Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.
McClellan on behalf of Ocular Therapeutix
Vice President of Sales and Marketing